中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1614-1622

Long-term prognosis of liver cirrhosis patients with spontaneous portosystemic shunt undergoing secondary endoscopic preventive therapy for type 1 isolated gastric variceal bleeding

DOI: 10.12449/JCH260718

  • Department of Gastroenterology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Key Project of the Digestive Medicine Coordinated Development Center,Beijing Hospitals Authority (XXZ0404)

More Information
  • Corresponding author: Ai Zhenglin， aizhenglin@126.com （ORCID： 0000-0002-9781-9658）
  • Received Date: 2025-11-17
  • Accepted Date: 2026-04-13
  • Published Date: 2026-07-25
    Abstract
  •   Objective  To observe the long-term survival outcomes and complications of liver cirrhosis patients with spontaneous portosystemic shunt and type 1 isolated gastric varices （IGV-1） bleeding after secondary endoscopic preventive therapy， and to investigate the independent influencing factors for long-term prognosis.  Methods  A total of 70 liver cirrhosis patients with spontaneous portosystemic shunt and IGV-1 bleeding who were admitted to Beijing Ditan Hospital， Capital Medical University， from January 5， 2015 to November 29， 2019 were enrolled as subjects， and related baseline data were collected， including age， sex， etiology， routine blood test results， liver function parameters， renal function parameters， coagulation parameters， Child-Pugh score， and the presence or absence of comorbidities such as cholestasis， hepatocellular carcinoma， thrombosis， ascites， and hepatic encephalopathy. All patients underwent secondary endoscopic preventive therapy for rebleeding and were followed up for 5 years. The primary endpoints were ectopic embolism rate and all-cause mortality rate， and the secondary endpoints were liver-related mortality and liver-related complications. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between groups， and the chi-square test was used for comparison of categorical data between groups. The Cox regression analysis was used to investigate the prognostic factors for 1-， 3-， and 5-year survival time， and the Logistic regression analysis was used to identify the independent risk factors for liver disease-related complications.  Results  The incidence rate of ectopic embolism was 0% within 5 years of follow-up. The 1-， 3-， and 5-year all-cause mortality rates were 5.7%， 24.3%， and 32.9%， respectively. There were 2 cases of liver-related death in year 1， 8 cases in year 3， and 12 cases in year 5， resulting in a liver disease-related mortality rate of 17.14% （12/70）. Compared with the survival group， the death group had significantly higher incidence rates of hepatocellular carcinoma （0.00% vs 17.39%， χ2=8.669， P=0.003） and ascites （38.30% vs 52.17%， χ2=7.272， P=0.026）， and compared with the death group， the survival group had significantly lower 5-year incidence rates of rebleeding （10.64% vs100.00%， χ2=51.383， P<0.001）， ascites （8.51% vs 52.17%， χ2=21.574， P<0.001）， and hepatic encephalopathy （0.00% vs 21.74%， χ2=12.029， P=0.002）. The multivariate Cox regression analysis showed that during the 1-year follow-up， comorbidity with hepatocellular carcinoma before surgery （hazard ratio ［HR］=14.601， 95% confidence interval ［CI］： 2.049 — 104.098， P=0.007） and PT （HR=1.662， 95%CI： 1.090 — 2.535， P=0.018） were independent risk factors for survival， and HGB level （HR=0.863， 95%CI： 0.747 — 0.998， P=0.046） was a protective factor for prolonged survival； during the long-term follow-up for 3 or 5 years， preoperative comorbidities with hepatocellular carcinoma （3 years： HR=40.174， 95%CI： 8.939 — 180.559， P<0.001； 5 years： HR=26.739， 95%CI： 6.993 — 102.243， P<0.001） and ascites （3 years： HR=3.638， 95%CI： 1.751 — 7.575， P=0.001； 5 years： HR=2.555， 95%CI： 1.419 — 4.598， P=0.002） were independent risk factors for mortality. The Logistic regression analysis showed that during the follow-up for 3 years， comorbidity with ascites before surgery （odds ratio ［OR］=0.255， 95%CI： 0.102 — 0.636， P=0.003） was associated with a lower risk of rebleeding， while comorbidity with hepatocellular carcinoma before surgery （OR=16.231， 95%CI： 1.298 — 202.878， P=0.031） was an independent risk factor for rebleeding； prothrombin time was a protective factor against hepatic encephalopathy （OR=0.790， 95%CI： 0.648 — 0.964， P=0.020）； during the follow-up for 5 years， aggravation of ascites after surgery （OR=5.578， 95%CI： 1.474 — 21.103， P=0.011） was an independent risk factor for rebleeding， and aggravation of ascites after surgery （OR=175.046， 95%CI： 14.306 — 2 141.909， P<0.001） were independent risk factors for the development of ascites in the future.  Conclusion  Comorbidity with hepatocellular carcinoma before surgery and prothrombin time are independent risk factors for 1-year survival， whereas a high HGB level is a protective factor for increasing 1-year survival. Preoperative comorbidities with hepatocellular carcinoma and ascites are independent risk factors for the long-term prognosis of patients with spontaneous portosystemic shunt and IGV-1 bleeding and can significantly shorten survival time. Preoperative comorbidity with ascites can reduce the occurrence of rebleeding， while postoperative hepatocellular carcinoma and aggravation of ascites after surgery are independent risk factors for rebleeding； aggravation of ascites after surgery is an independent risk factor for the development of ascites in the future.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    Sarin S K, Lahoti D, Saxena S P, et al. Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients[J]. Hepatology, 1992, 16( 6): 1343- 1349. DOI: 10.1002/hep.1840160607.
    [2]
    Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65( 1): 310- 335. DOI: 10.1002/hep.28906.
    [3]
    Lee E W, Shahrouki P, Alanis L, et al. Management options for gastric variceal hemorrhage[J]. JAMA Surg, 2019, 154( 6): 540. DOI: 10.1001/jamasurg.2019.0407.
    [4]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. Chin J Intern Med, 2023, 62( 1): 7- 22. DOI: 10.3760/cma.j.cn501113-20220824-00436.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 中华内科杂志, 2023, 62( 1): 7- 22. DOI: 10.3760/cma.j.cn501113-20220824-00436.
    [5]
    de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII–Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [6]
    Gralnek I M, Camus Duboc M, Garcia-Pagan J C, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy(ESGE) Guideline[J]. Endoscopy, 2022, 54( 11): 1094- 1120. DOI: 10.1055/a-1939-4887.
    [7]
    Ma Jiali, Ai Zhenglin, Hu Julong, et al. The preliminary therapeutic effect of endoscopic ultrasound-guided tissue adhesive injection with the assistance of metal clips in treatment of cirrhotic patients with gastric varices and gastric-renal shunt[J]. J Clin Hepatol, 2024, 40( 4): 734- 738. DOI: 10.12449/JCH240415.

    马佳丽, 艾正琳, 胡居龙, 等. 金属夹辅助内镜超声引导组织胶注射治疗合并胃肾分流的肝硬化胃静脉曲张患者的效果初探[J]. 临床肝胆病杂志, 2024, 40( 4): 734- 738. DOI: 10.12449/JCH240415.
    [8]
    Ai Zhenglin, Min Min, Hu Julong, et al. Efficacy evaluation of three endoscopic therapies of isolated gastric varices with modified tissue adhesive[J]. J Sichuan Univ Med Sci, 2022, 53( 3): 386- 390. DOI: 10.12182/20220560102.

    艾正琳, 闵敏, 胡居龙, 等. 三种内镜下改良组织胶方案治疗孤立性胃静脉曲张的疗效评价[J]. 四川大学学报(医学版), 2022, 53( 3): 386- 390. DOI: 10.12182/20220560102.
    [9]
    Ai Z L, Li P. Loop combined endoscopic clip and cyanoacrylate injection to treat severe gastric varices with spleno-renal shunt[J]. VideoGIE, 2020, 5( 12): 652- 654. DOI: 10.1016/j.vgie.2020.07.020.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites in cirrhosis(2023 version)[J]. Chin J Hepatol, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.

    中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.
    [11]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of hepatic encephalopathy in cirrhosis(2024)[J]. Chin J Hepatol, 2024, 32( 9): 799- 812. DOI: 10.3760/cma.j.cn501113-20240630-00309.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32( 9): 799- 812. DOI: 10.3760/cma.j.cn501113-20240630-00309.
    [12]
    Xia Y F, Tie J, Wang G C, et al. Small transjugular intrahepatic portosystemic shunt plus variceal embolization for gastric varices: A multicenter cohort study[J]. Clin Gastroenterol Hepatol, 2025, 23( 6): 965- 977.e20. DOI: 10.1016/j.cgh.2024.04.037.
    [13]
    Zhu J Y, Xia Y F, Wang G C, et al. TIPS versus endoscopic cyanoacrylate injection for the treatment of gastric fundal variceal rebleeding: A propensity score-matched retrospective cohort study[J]. Surg Endosc, 2025, 39( 6): 3662- 3670. DOI: 10.1007/s00464-025-11761-x.
    [14]
    Li M, Wei Z H, Su J T, et al. Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China[J]. J Med Virol, 2024, 96( 1): e29405. DOI: 10.1002/jmv.29405.
    [15]
    Zheng Wenmin, Tian Yuanyuan. Age-period-cohort analysis and prediction of incidence and mortality of cirrhosis in China, 1990-2019[J]. Dis Surveillance, 2024, 39( 11): 1489- 1494. DOI: 10.3784/jbjc.202401290061.

    郑文敏, 田元元. 1990—2019年中国肝硬化发病和死亡年龄-时期-队列分析及预测[J]. 疾病监测, 2024, 39( 11): 1489- 1494. DOI: 10.3784/jbjc.202401290061.
    [16]
    Huang D Q, Terrault N A, Tacke F, et al. Global epidemiology of cirrhosis: Aetiology, trends and predictions[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 6): 388- 398. DOI: 10.1038/s41575-023-00759-2.
    [17]
    Fadlallah H, El Masri D, Bahmad H F, et al. Update on the complications and management of liver cirrhosis[J]. Med Sci, 2025, 13( 1): 13. DOI: 10.3390/medsci13010013.
    [18]
    Hernaez R, Liu Y, Kramer J R, et al. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure[J]. J Hepatol, 2020, 73( 6): 1425- 1433. DOI: 10.1016/j.jhep.2020.06.005.
    [19]
    Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
    [20]
    Patidar K R, Belcher J M, Regner K R, et al. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US[J]. J Hepatol, 2023, 79( 6): 1408- 1417. DOI: 10.1016/j.jhep.2023.07.010.
    [21]
    Liu N, Wu S, Guo J. Spillover health losses of COVID-19 in China: Evidence from non-COVID-19-related mortality[J]. Public Heal, 2024, 235: 8- 14. DOI: 10.1016/j.puhe.2024.06.026.
    [22]
    Gupta T, Sharma H. COVID-19 and the liver: Are footprints still there?[J]. World J Gastroenterol, 2023, 29( 4): 656- 669. DOI: 10.3748/wjg.v29.i4.656.
    [23]
    Su F. COVID-19 and cirrhosis: A combination we must strive to prevent[J]. Gastroenterology, 2021, 161( 5): 1371- 1373. DOI: 10.1053/j.gastro.2021.08.037.
    [24]
    Rodrigues S G, Mendoza Y P, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations[J]. JHEP Rep, 2020, 2( 1): 100063. DOI: 10.1016/j.jhepr.2019.12.001.
    [25]
    Møller S, Wiese S, Barløse M, et al. How non-alcoholic fatty liver disease and cirrhosis affect the heart[J]. Hepatol Int, 2023, 17( 6): 1333- 1349. DOI: 10.1007/s12072-023-10590-1.
    [26]
    Xian J C, Tang Y Z, Shao H, et al. Effect of portal vein thrombosis on the prognosis of patients with cirrhosis without a liver transplant: A systematic review and meta-analysis[J]. Medicine, 2021, 100( 16): e25439. DOI: 10.1097/MD.0000000000025439.
    [27]
    Verma N, Singh S, Roy A, et al. Cirrhosis and fungal infections-a cocktail for catastrophe: A systematic review and meta-analysis with machine learning[J]. Mycoses, 2022, 65( 9): 844- 858. DOI: 10.1111/myc.13482.
    [28]
    Verma N, Singh S, Syal A, et al. Invasive aspergillosis is a critical determinant of mortality in cirrhosis: A systematic review with meta-analysis[J]. Med Mycol, 2021, 59( 11): 1092- 1100. DOI: 10.1093/mmy/myab044.
    [29]
    Ardevol A, Alvarado-Tapias E, Garcia-Guix M, et al. Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation[J]. Dig Liver Dis, 2020, 52( 9): 1017- 1025. DOI: 10.1016/j.dld.2020.06.005.
    [30]
    O’Shea R S, Davitkov P, Ko C W, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis[J]. Gastroenterology, 2021, 161( 5): 1615- 1627.e1. DOI: 10.1053/j.gastro.2021.08.015.
    [31]
    Guerrero A, del Campo L, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis[J]. J Hepatol, 2023, 79( 1): 69- 78. DOI: 10.1016/j.jhep.2023.02.023.
    [32]
    Gupta A, Rana R, Agarwal S, et al. Assessing the risk of further decompensation and survival in patients with cirrhosis with variceal bleeding as their first decompensation event[J]. Am J Gastroenterol, 2023, 118( 5): 833- 839. DOI: 10.14309/ajg.0000000000002018.
    [33]
    Tapper E B, Parikh N D. Diagnosis and management of cirrhosis and its complications: A review[J]. JAMA, 2023, 329( 18): 1589- 1602. DOI: 10.1001/jama.2023.5997.
    [34]
    Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension(2025 edition)[J]. Chin J Dig Surg, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590.

    中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2025版)[J]. 中华消化外科杂志, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590.
    [35]
    Yokoyama S, Honda T, Ishizu Y, et al. Predicting early rebleeding and mortality after endoscopic hemostasis of esophagogastric varices: Diagnostic performance of aspartate aminotransferase-to-platelet ratio index and model for end-stage liver disease-Na score[J]. J Hepato Biliary Pancreat Sci, 2024, 31( 11): 830- 839. DOI: 10.1002/jhbp.12057.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (70) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return